Key result
Rivaroxaban combined with aspirin reduced cardiovascular events without increasing the risk of fatal and intracranial bleeding in patients with coronary or peripheral artery disease.
Why the study?
Does rivaroxaban combined with aspirin reduce cardiovascular events in patients with established cardiovascular disease?
Does rivaroxaban combined with aspirin reduce cardiovascular events in patients with established cardiovascular disease?
This review highlights that adding rivaroxaban to aspirin reduces cardiovascular events in patients with established cardiovascular disease without increasing fatal or intracranial bleeding.
May support rivaroxaban plus aspirin in CAD/PAD; leaves open need for prospective confirmation and guideline updates.
Patients with established cardiovascular disease may suffer further cardiovascular events, despite receiving optimal medical treatment. Although platelet inhibition plays a central role in the prevention of new events, the use of anticoagulant therapies to reduce events in atheromatous disease has, until recently, been overlooked. The recent Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS) study showed an important reduction in cardiovascular events without increasing the risk of fatal and intracranial bleeding when using rivaroxaban, a novel oral anticoagulant, combined with aspirin. This article reviews the available evidence regarding the use of anticoagulant therapies for prevention of cardiovascular events, the results of the COMPASS study and how these results may affect patient management in everyday clinical practice.
No takes yet. Share an insight, caveat, or question.
Gradolí et al. (2018) conducted a review in Ischaemic Heart Disease and Peripheral Arterial Disease. Rivaroxaban combined with aspirin was evaluated on Cardiovascular events. Rivaroxaban combined with aspirin reduced cardiovascular events without increasing the risk of fatal and intracranial bleeding in patients with coronary or peripheral artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: